Experimental drug shows promise in treating head, neck cancers
April 29th, 2009 - 2:34 pm ICT by ANIWashington, April 29 (ANI): An anti-cancer compound studied for treating blood cancers may also help in treating cancers of the head and neck, say researchers at Albert Einstein College of Medicine of Yeshiva University.
The study involved a new class of chemotherapy agents known as histone deacetylase (HDAC) inhibitors, which affect the availability of genes that are transcribed and translated into proteins.
In many types of cancer, out-of-control cell growth results from certain genes that are either too active or not active enough in producing proteins.
HDAC inhibitors appear to combat cancer by restoring the normal expression of key regulatory genes that control cell growth and survival.
The researchers focused on a particular HDAC inhibitor known as LBH589 that has already shown some success in clinical trials involving people with cancers of the blood.
The researchers found that LBH589 succeeded in killing tumour cells that had been removed from head and neck cancer patients and grown in the laboratory.
“This report shows that an HDAC inhibitor is effective on head and neck cancer cell lines, and that is the first step toward use in humans,” said Richard Smith, M.D., the lead clinician involved in the study.
The researchers also identified a set of genes whose expression levels change in response to the HDAC inhibitors-a finding that may help doctors identify patients most likely to respond to the drug.
Plans call for testing LBH589 on head and neck tumour cells from more patients so that the set of genes that respond to the drug can be more firmly established.
Michael Prystowsky, M.D., Ph.D., chair and professor of pathology at Einstein and co-author of the study, said: “We are performing studies in mice to confirm these laboratory results, which hopefully will progress to human clinical trials of LBH589 for the treatment of head and neck cancer,” said
The study is reported in the April 28th online edition of the Journal of Pathology. (ANI)
- Cancer drug can reverse heart failure - May 31, 2011
- Scientists complete whole-exome sequencing of skin cancer - Apr 16, 2011
- DNA damage can help protect the body from infection - Apr 01, 2011
- Scientists stumble upon 'stop cancer' gene - Nov 16, 2011
- Key component in the spread of lung cancer discovered - Mar 15, 2011
- Combo therapy may overcome Herceptin-resistant breast cancer - Mar 14, 2011
- Revolutionary therapy shows promise for breast cancer patients: Lancet - Jul 06, 2010
- How melanoma tumours evade drug treatment - Nov 25, 2010
- Molecular 'playbook' to stop heart failure risk factor found - Sep 24, 2010
- Wonder drug could kill all types of cancer - Jun 27, 2011
- Mechanism for esophageal cancer identified - Apr 12, 2011
- Intestinal stem cells offer clues to colon cancer origin and relapse - Mar 18, 2011
- Protein biomarkers in exhaled air to help detect lung cancer early - Feb 03, 2011
- Herpes virus helps treat cancer patients - Aug 03, 2010
- Circulating tumour cells tied to poorer survival in pancreatic cancer sufferers - May 29, 2010
Tags: albert einstein, albert einstein college, albert einstein college of medicine, albert einstein college of medicine of yeshiva universi, blood cancers, cancer cell, chemotherapy agents, co author, college of medicine, einstein college of medicine, experimental drug, expression levels, head and neck cancer, laboratory results, neck cancer patients, neck cancers, regulatory genes, richard smith, tumour cells, types of cancer
